David Enloe, Societal CDMO CEO

So­ci­etal nabs sole sup­pli­er role for Ri­tal­in to Eu­rope

Un­til the end of 2023, So­ci­etal will be the sole sup­pli­er of Ri­tal­in to Eu­rope.

The CD­MO an­nounced on Thurs­day that it’s en­tered a three-year man­u­fac­tur­ing and sup­ply deal with In­fec­toPharm for the at­ten­tion deficit hy­per­ac­tiv­i­ty dis­or­der drug to re­main the sole sup­pli­er of the drug through the end of next year. The deal runs through the end of April 2025; So­ci­etal will con­tin­ue sup­ply­ing Ri­tal­in af­ter its ex­clu­siv­i­ty ends next year along with oth­er sup­pli­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.